Predictive Role of Non-Invasive Glucose Assessment During Pregnancy

Overview

About this study

This study aims to determine the value of regular, non-invasive [glucose] LabClasp monitoring during pregnancy.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Age range: 18-45 years (inclusive).
  • Body mass index (BMI) ≤ 40kg/m^2.
  • > 1 risk factor for GDM.
  • < 16 weeks gestation.
  • Only females will be recruited into this study.
  • Target disease or condition: pregnancy  
  • Individuals with treated hypertension, prehypertension, and dyslipidemia will be allowed to participate in the study.
  • Ability to provide written informed consent .

Exclusion Criteria:

  • Presence of chronic kidney disease (creatinine > 2.5mg/dL) and/or active cancer.
  • Smoking.
  • Multiple pregnancies.
  • Congenital abnormalities.
  • Use of chronic medications which influence blood [glucose] or [insulin].
  • Subsequent diagnosis of GDM.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Virend Somers, M.D., Ph.D.

Contact us for the latest status

Contact information:

Nicholas Wozniak

(507) 255-8794

Wozniak.Nicholas@mayo.edu

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

.
CLS-20518127

Mayo Clinic Footer